Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 3.000%10/1
-
Market price (% of par)
-
73.0%
-
Total 13F principal
-
$101,389,000
-
Principal change
-
-$59,422,700
-
Total reported market value
-
$78,918,752
-
Number of holders
-
11
-
Value change
-
-$54,523,098
-
Number of sells
-
11
Institutional Holders of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 as of Q2 2022
As of 30 Jun 2022,
KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 was held by
11 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$101,389,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, Davidson Kempner Capital Management LP, LAZARD ASSET MANAGEMENT LLC, DeepCurrents Investment Group LLC, Birch Grove Capital LP, CAPSTONE INVESTMENT ADVISORS, LLC, JPMORGAN CHASE & CO, Federation des caisses Desjardins du Quebec, MACKAY SHIELDS LLC, and BLB&B Advisors, LLC.
This page lists
11
institutional bondholders reporting positions
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.